CG Oncology Reports 2025 Financial Results and Clinical Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CGON?
Source: Newsfilter
- Clinical Trial Progress: CG Oncology anticipates releasing topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy for intermediate-risk NMIBC in the first half of 2026, highlighting the company's innovative potential in this field.
- Strong Financial Position: As of February 26, 2026, the company reported approximately $903 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2029, demonstrating robust financial strength and ongoing R&D capabilities.
- Increased R&D Expenses: R&D expenses for Q4 2025 reached $30 million, up from $26.8 million in the prior year, primarily due to rising clinical trial costs and personnel expenses, reflecting the company's commitment to new drug development.
- Board Enhancement: In November 2025, CG Oncology appointed Christina Rossi to its board, who brings extensive experience in the life sciences sector, expected to drive the company's strategic execution in drug commercialization and market outreach.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGON
Wall Street analysts forecast CGON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.800
Low
65.00
Averages
79.73
High
108.00
Current: 58.800
Low
65.00
Averages
79.73
High
108.00
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CG Oncology Reports FY Earnings with Significant Revenue Growth
- Earnings Highlights: CG Oncology's FY GAAP EPS of -$2.08 beats expectations by $0.09, indicating some progress in cost management despite still being in a loss position.
- Revenue Surge: The company reported FY revenue of $4.04M, a remarkable 254.4% year-over-year increase, surpassing market expectations by $1.24M, showcasing strong demand and sales capability for its products.
- Clinical Trial Progress: At the 44th Annual J.P. Morgan Healthcare Conference, CG Oncology presented advancements in its lead asset Cretostimogene, having completed recruitment earlier than expected, which may expedite its market launch.
- Positive Market Reaction: Following the acceleration of its key asset's clinical trial, CG Oncology's stock price rose, reflecting increased investor confidence in the company's future growth potential.
See More
CG Oncology Reports 2025 Financial Results and Clinical Progress
- Clinical Trial Progress: CG Oncology anticipates releasing topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy for intermediate-risk NMIBC in the first half of 2026, highlighting the company's innovative potential in this field.
- Strong Financial Position: As of February 26, 2026, the company reported approximately $903 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2029, demonstrating robust financial strength and ongoing R&D capabilities.
- Increased R&D Expenses: R&D expenses for Q4 2025 reached $30 million, up from $26.8 million in the prior year, primarily due to rising clinical trial costs and personnel expenses, reflecting the company's commitment to new drug development.
- Board Enhancement: In November 2025, CG Oncology appointed Christina Rossi to its board, who brings extensive experience in the life sciences sector, expected to drive the company's strategic execution in drug commercialization and market outreach.
See More
CG Oncology Inc. Reports $903 Million in Cash and Marketable Securities to Support Operations Through First Half of 2029
Financial Overview: C Oncology Inc. has reported a cash position of $903 million, which includes cash equivalents and marketable securities.
Operational Funding: The available funds are deemed sufficient to support operations into the first half of 2029.
See More
Wolverine World Wide Sees Surge in Options Trading Volume
- Surge in Options Volume: Wolverine World Wide (WWW) experienced an options trading volume of 11,306 contracts today, equating to approximately 1.1 million shares, which represents about 89.9% of its average daily trading volume over the past month, indicating strong market interest in its stock.
- High Put Option Activity: Notably, the $17.50 strike put option has seen significant trading, with 6,111 contracts exchanged today, representing around 611,100 shares, reflecting investor expectations of potential downward price movement.
- AdaptHealth Options Activity: Concurrently, AdaptHealth Corp (AHCO) also witnessed notable options trading, with a volume of 7,945 contracts, equivalent to approximately 794,500 shares, accounting for 82.8% of its average daily trading volume over the past month, highlighting active market engagement.
- Active Call Option Trading: The $10 strike call option for AHCO has been particularly active, with 7,847 contracts traded today, representing about 784,700 shares, suggesting a bullish sentiment among investors regarding its future stock price appreciation.
See More
Braidwell Reduces Stake in CG Oncology
- Share Reduction Details: Braidwell disclosed in its February 17, 2026 SEC filing that it reduced its position in CG Oncology by 1,412,746 shares during Q4 2025, with an estimated transaction value of $58.46 million, indicating a potential shift in confidence towards the company.
- Value Decline Impact: This reduction resulted in a $54.59 million decline in Braidwell's stake value in CG Oncology, highlighting the impact of market volatility on its investment portfolio and reflecting the stock's inherent fluctuations.
- Ownership Proportion Analysis: Post-sale, Braidwell's stake in CG Oncology now represents 2.48% of its reportable U.S. equity assets, indicating that despite the reduction, it still holds a significant position within its healthcare-heavy portfolio.
- Market Performance and Outlook: As of February 18, 2026, CG Oncology's shares were priced at $55.21, up 101.7% over the past year, demonstrating strong market interest in its clinical-stage therapeutic candidates, with upcoming data releases poised to significantly impact stock performance.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
CG Oncology Reports FY Earnings with Significant Revenue Growth
- Earnings Highlights: CG Oncology's FY GAAP EPS of -$2.08 beats expectations by $0.09, indicating some progress in cost management despite still being in a loss position.
- Revenue Surge: The company reported FY revenue of $4.04M, a remarkable 254.4% year-over-year increase, surpassing market expectations by $1.24M, showcasing strong demand and sales capability for its products.
- Clinical Trial Progress: At the 44th Annual J.P. Morgan Healthcare Conference, CG Oncology presented advancements in its lead asset Cretostimogene, having completed recruitment earlier than expected, which may expedite its market launch.
- Positive Market Reaction: Following the acceleration of its key asset's clinical trial, CG Oncology's stock price rose, reflecting increased investor confidence in the company's future growth potential.
See More
CG Oncology Reports 2025 Financial Results and Clinical Progress
- Clinical Trial Progress: CG Oncology anticipates releasing topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy for intermediate-risk NMIBC in the first half of 2026, highlighting the company's innovative potential in this field.
- Strong Financial Position: As of February 26, 2026, the company reported approximately $903 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2029, demonstrating robust financial strength and ongoing R&D capabilities.
- Increased R&D Expenses: R&D expenses for Q4 2025 reached $30 million, up from $26.8 million in the prior year, primarily due to rising clinical trial costs and personnel expenses, reflecting the company's commitment to new drug development.
- Board Enhancement: In November 2025, CG Oncology appointed Christina Rossi to its board, who brings extensive experience in the life sciences sector, expected to drive the company's strategic execution in drug commercialization and market outreach.
See More
CG Oncology Inc. Reports $903 Million in Cash and Marketable Securities to Support Operations Through First Half of 2029
Financial Overview: C Oncology Inc. has reported a cash position of $903 million, which includes cash equivalents and marketable securities.
Operational Funding: The available funds are deemed sufficient to support operations into the first half of 2029.
See More
Wolverine World Wide Sees Surge in Options Trading Volume
- Surge in Options Volume: Wolverine World Wide (WWW) experienced an options trading volume of 11,306 contracts today, equating to approximately 1.1 million shares, which represents about 89.9% of its average daily trading volume over the past month, indicating strong market interest in its stock.
- High Put Option Activity: Notably, the $17.50 strike put option has seen significant trading, with 6,111 contracts exchanged today, representing around 611,100 shares, reflecting investor expectations of potential downward price movement.
- AdaptHealth Options Activity: Concurrently, AdaptHealth Corp (AHCO) also witnessed notable options trading, with a volume of 7,945 contracts, equivalent to approximately 794,500 shares, accounting for 82.8% of its average daily trading volume over the past month, highlighting active market engagement.
- Active Call Option Trading: The $10 strike call option for AHCO has been particularly active, with 7,847 contracts traded today, representing about 784,700 shares, suggesting a bullish sentiment among investors regarding its future stock price appreciation.
See More
Braidwell Reduces Stake in CG Oncology
- Share Reduction Details: Braidwell disclosed in its February 17, 2026 SEC filing that it reduced its position in CG Oncology by 1,412,746 shares during Q4 2025, with an estimated transaction value of $58.46 million, indicating a potential shift in confidence towards the company.
- Value Decline Impact: This reduction resulted in a $54.59 million decline in Braidwell's stake value in CG Oncology, highlighting the impact of market volatility on its investment portfolio and reflecting the stock's inherent fluctuations.
- Ownership Proportion Analysis: Post-sale, Braidwell's stake in CG Oncology now represents 2.48% of its reportable U.S. equity assets, indicating that despite the reduction, it still holds a significant position within its healthcare-heavy portfolio.
- Market Performance and Outlook: As of February 18, 2026, CG Oncology's shares were priced at $55.21, up 101.7% over the past year, demonstrating strong market interest in its clinical-stage therapeutic candidates, with upcoming data releases poised to significantly impact stock performance.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
